Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1915 1
1944 1
1945 1
1946 1
1947 4
1948 3
1949 3
1951 2
1952 1
1954 2
1955 2
1956 4
1957 2
1958 1
1960 1
1962 1
1963 2
1964 4
1966 4
1967 2
1968 2
1970 3
1973 3
1974 3
1975 4
1976 1
1977 2
1978 1
1979 1
1980 2
1981 7
1982 2
1983 5
1984 9
1985 7
1986 4
1987 7
1988 11
1989 13
1990 9
1991 6
1992 8
1993 7
1994 17
1995 16
1996 16
1997 21
1998 20
1999 15
2000 15
2001 22
2002 21
2003 32
2004 41
2005 36
2006 40
2007 49
2008 60
2009 61
2010 68
2011 62
2012 67
2013 87
2014 84
2015 93
2016 88
2017 103
2018 111
2019 107
2020 94
2021 68
Text availability
Article attribute
Article type
Publication date

Search Results

1,506 results
Results by year
Filters applied: . Clear all
Page 1
Treating cancer with selective CDK4/6 inhibitors.
O'Leary B, Finn RS, Turner NC. O'Leary B, et al. Among authors: turner nc. Nat Rev Clin Oncol. 2016 Jul;13(7):417-30. doi: 10.1038/nrclinonc.2016.26. Epub 2016 Mar 31. Nat Rev Clin Oncol. 2016. PMID: 27030077 Review.
Molecular Testing in Breast Cancer.
Litton JK, Burstein HJ, Turner NC. Litton JK, et al. Among authors: turner nc. Am Soc Clin Oncol Educ Book. 2019 Jan;39:e1-e7. doi: 10.1200/EDBK_237715. Epub 2019 May 17. Am Soc Clin Oncol Educ Book. 2019. PMID: 31099622 Free article. Review.
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, André F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M. Turner NC, et al. N Engl J Med. 2018 Nov 15;379(20):1926-1936. doi: 10.1056/NEJMoa1810527. Epub 2018 Oct 20. N Engl J Med. 2018. PMID: 30345905 Clinical Trial.
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D. Cristofanilli M, et al. Among authors: turner nc. Lancet Oncol. 2016 Apr;17(4):425-439. doi: 10.1016/S1470-2045(15)00613-0. Epub 2016 Mar 3. Lancet Oncol. 2016. PMID: 26947331 Clinical Trial.
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC. Merker JD, et al. Among authors: turner nc. J Clin Oncol. 2018 Jun 1;36(16):1631-1641. doi: 10.1200/JCO.2017.76.8671. Epub 2018 Mar 5. J Clin Oncol. 2018. PMID: 29504847 Review.
Impairment of an Endothelial NAD+-H2S Signaling Network Is a Reversible Cause of Vascular Aging.
Das A, Huang GX, Bonkowski MS, Longchamp A, Li C, Schultz MB, Kim LJ, Osborne B, Joshi S, Lu Y, Treviño-Villarreal JH, Kang MJ, Hung TT, Lee B, Williams EO, Igarashi M, Mitchell JR, Wu LE, Turner N, Arany Z, Guarente L, Sinclair DA. Das A, et al. Among authors: turner n. Cell. 2018 Mar 22;173(1):74-89.e20. doi: 10.1016/j.cell.2018.02.008. Cell. 2018. PMID: 29570999 Free PMC article.
1,506 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page